Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug:251:15-18.
doi: 10.1016/j.atherosclerosis.2016.05.005. Epub 2016 May 11.

Lomitapide affects HDL composition and function

R Yahya  1 , E Favari  2 , L Calabresi  3 , A J M Verhoeven  1 , F Zimetti  2 , M P Adorni  2 , M Gomaraschi  3 , M Averna  4 , A B Cefalù  4 , F Bernini  2 , E J G Sijbrands  1 , M T Mulder  1 , J E Roeters van Lennep  5
Affiliations
Free article

Lomitapide affects HDL composition and function

R Yahya et al. Atherosclerosis. 2016 Aug.
Free article

Abstract

Background: Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH).

Methods and results: Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range -34 to -89%). Total HDL-C levels decreased (range -16 to -34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range -39 to -99%). The changes of total, ABCG1- and SR-BI-mediated CEC were less consistent.

Conclusion: Lomitapide decreased LDL-C and HDL-C levels. Our report raises the hypothesis that the anti-atherogenic potential of HDL seems to be unaffected as total CEC did not seem to change consistently. Combined with the reduction of atherogenic lipoproteins, the net effect of lomitapide appears to be beneficial in HoFH patients.

Keywords: Cholesterol efflux capacity; Cholesterol lowering drugs; HDL; Homozygous familial hypercholesterolemia; Lomitapide.

PubMed Disclaimer